+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Next Generation Cancer Diagnostics: Technologies and Global Markets

  • ID: 5138101
  • Report
  • August 2020
  • Region: Global
  • 318 pages
  • BCC Research
1 of 4

FEATURED COMPANIES

  • 20/20 Gene Systems
  • BGI Shenzhen
  • Cellular Analytics
  • Geneoscopy Llc
  • Miradx
  • Predicine Inc.
  • MORE
Report Scope:

The scope of this report includes next generation diagnostic technologies, applications, industry subsegments, major funding initiatives, patents and companies. The market sizes for next generation cancer diagnostics are given for 2019, 2020 (estimated) and 2025 (forecasted).

This report reviews the main next generation diagnostic technologies, including next generation sequencing (NGS), polymerase chain reaction (PCR), multiplex conventional, cell or extracellular vesicle capture and arrays/microfluidics. The report also discusses, in-depth, various liquid biopsy platforms and how these compare with tissue-based testing.

The report discusses several significant, large-scale research initiatives that contribute to cancer diagnostic development. Key forces driving the market are enumerated.

The structures of several important industry subsectors are reviewed, as well as major industry acquisitions and strategic alliances from Jan. 2019 through June 2020. The industry subsectors analyzed include DNA sequencing instruments, long-read DNA sequencing, informatics, PCR, droplet digital PCR, CTC capture and detection and liquid biopsy.

The market for next generation cancer diagnostics is analyzed in depth. The market is analyzed by cancer site (bladder, brain, breast, colorectal, cancer of unknown primary, gastric, gynecologic, hematologic, kidney, liver, lung, pan-cancer, pancreatic, prostate, melanoma and thyroid), by test purpose (screening/early detection, diagnosis, monitoring, therapy guidance), by test platform (arrays/microfluidics, cell/EV capture, multiplex conventional, PCR and NGS) and by geography (North America, Europe, Asia Pacific, Rest of World).

Market data covers 2019, 2020 (estimated) and 2025 (forecasted).

There is a special section discussing the impact of COVID-19 on the market for next generation cancer diagnostics.

More than 130 companies in the next generation cancer diagnostics industry are profiled in this report.

The research provides a summary of the main industry acquisitions and strategic alliances from Jan. 2019 through June 2020, including key alliance trends.

Report Includes:
  • 22 data tables and 74 additional tables
  • An overview of the global market and technologies for next generation cancer diagnostics
  • Analyses of global market trends, with data from 2019, estimates for 2020, and projections of compound annual growth rates (CAGRs) through 2025
  • Analyses of the next generation cancer diagnostics market by cancer site, analysis purpose, analysis platform and region
  • Discussion on arrays and microfluidics (LOAC) technologies, multiplex conventional technologies, next generation sequencing technology and polymerase chain reaction (PCR) technology
  • Evaluation of current market trends, market size, market forecast, pipeline analysis of new products, and regulatory scenarios of the cancer diagnostics market
  • Discussion on factors affecting the market including cancer diagnostics needs, regulatory trends, industry structure, and patent statuses
  • Details of the key initiatives and programs related to the next generation cancer diagnostics market
  • Market share analysis of the key companies of the industry, their strategic profiling, competitive landscape, and their detailed company profiles, including Abbott Laboratories, Illumina Inc., Myriad Genetics Inc., Qiagen NV, Oche Holding AG, and Thermo Fisher Scientific Inc.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 20/20 Gene Systems
  • BGI Shenzhen
  • Cellular Analytics
  • Geneoscopy Llc
  • Miradx
  • Predicine Inc.
  • MORE
Chapter 1 Introduction
  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • Custom Research
  • Related Reports
Chapter 2 Summary and Highlights

Chapter 3 Overview
  • Large-Scale Initiatives and Consortia
  • Market Size
  • Liquid Biopsy as a Market Driving Force
  • Key Trends
  • Industry
Chapter 4 Technologies
  • Diagnostics Overview
  • Arrays and Microfluidics (LOAC) Technologies
  • DNA Microarrays
  • Protein Microarrays
  • Microfluidics
  • Multiplex Conventional Technologies
  • Next Generation Sequencing Technology
  • Polymerase Chain Reaction (PCR) Technology
Chapter 5 Liquid Biopsy Technologies
  • Liquid Biopsy Biomarkers
  • Cancer Genomics
  • Circulating Tumor Cell Technologies
  • CTC Workflow
  • Cell Isolation Technologies
  • CTC Sample Preparation Technologies
  • CTC Downstream Analysis Technologies
  • Comparison of Liquid Biopsy with Conventional Biopsy
  • Cancer Testing
  • Avatar-Driven Diagnostic Approaches
Chapter 6 Next Generation Cancer Diagnostics: Key Initiatives and Programs
  • Blood Profiling Atlas
  • Cancer-ID
  • Cancer Moon Shots
  • China Precision Medicine Initiative
  • ClinGen
  • CTC Trap Consortium
  • Early Cancer Detection Consortium
  • EpiFemCare
  • France Genomic Medicine Plan
  • Friends of Cancer Research Project
  • Human Cell Atlas
  • Immunomonitor Consortium
  • Integration of Imaging and Fluid-Based Tumor Monitoring
  • Liquid Biopsies and Imaging for Improved Cancer Care
  • Million Veteran Program
  • MedSeq
  • Next-Generation Single-Cell Analysis Program
  • Population Sequencing Projects
  • Precancer Atlas
  • Precision Medicine Initiative
  • Prompt
  • QuIP Project
  • Single-Cell Proteomics and Lipidomics Project
  • TopMed
  • Treehouse Childhood Cancer Initiative
  • Very Rare Cancer Consortium
  • Worldwide Innovative Networking (WIN) Consortium
  • Single-Cell Research
  • Cambridge Single-Cell Analysis Core Facility
  • Harvard Medical School Single-Cell Core
  • Mayo Medical Genome Facility
  • National Center for Single-Cell Biology
  • Single-Cell Analysis Core
  • UC San Francisco Single-Cell Analysis Center
  • Population Sequencing Programs
Chapter 7 Next Generation Cancer Diagnostic Applications by Cancer Site
  • Introduction
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Breast Cancer Screening
  • Prognosis and Pharmacogenetics Tests
  • Breast Cancer MDx Platforms
  • Status of Next Generation Breast Cancer Tests
  • Breast Cancer Early Detection and Screening Tests
  • Breast Cancer Risk Tests
  • Response to Chemotherapy, Recurrence Probability and Subtyping
  • Gynecologic Cancers
  • Cervical Cancer
  • Ovarian Cancer
  • Colorectal Cancer
  • Conventional Colorectal Cancer Screening Tests
  • Next Generation Colorectal Cancer Diagnostic Tests
  • Cancer Unknown Primary
  • Gastric Cancer
  • Kidney Cancer
  • Hematologic Tests: Leukemia and Myeloma
  • Liver Cancer
  • Lung Cancer
  • Hematologic Tests: Lymphomas
  • Melanoma
  • Pan-Cancer
  • Prostate Cancer
  • Thyroid Cancer
Chapter 8 Cancer Diagnostics Industries
  • Sequencing Instruments Industry
  • Long Read Sequencing Industry
  • Sequencing Informatics Industry
  • PCR Industry
  • Droplet Digital PCR Industry
  • CTC Capture and Detection Industry
  • Liquid Biopsy Assay Industry
Chapter 9 Industry Acquisitions and Strategic Alliances
  • Acquisitions
  • Strategic Alliances
Chapter 10 Cancer Diagnostics Markets
  • Forces Driving Growth
  • COVID-19 Impact on Cancer Diagnostic Markets
  • Cancer Markets
  • Market for Next Generation Cancer Diagnostics by Cancer Site
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Gynecologic Cancers
  • Cancer of Unknown Primary
  • Gastric Cancer
  • Hematologic Cancers
  • Kidney Cancer
  • Liver Cancer
  • Lung Cancer
  • Melanoma
  • Pan-Cancer
  • Pancreatic Cancer
  • Prostate Cancer
  • Thyroid Cancer
  • Market for Next Generation Cancer Diagnostics by Purpose of Analysis
  • Screening/Early Detection Market
  • Diagnosis Market
  • Therapy Guidance Market
  • Monitoring Market
  • Market for Next Generation Cancer Diagnostics by Test Platform
  • PCR Test Platform
  • NGS Test Platform
  • Array/Microfluidics Test Platform
  • Cells and/or EV Capture Test Platform
  • Multiplex Conventional Test Platform
  • Market for Test Platforms by Cancer Site
  • PCR Test Platform
  • NGS Test Platform
  • Market by Diagnostic Segment
  • Screening/Early Detection Market
  • Diagnostics Market
  • Monitoring Market
  • Therapy Guidance Market
  • Breast Cancer Diagnostics
  • Colorectal Cancer Diagnostics
  • Lung Cancer Diagnostics
  • Pan-Cancer Diagnostics
  • Prostate Cancer Diagnostics
  • Regional Market Analysis
Chapter 11 Patents
  • Circulating Tumor Cell Patents
  • Exosome Patents
  • Cell-free DNA (cfDNA) Patents
  • Biomarker-Related Patents
  • Patent Considerations: AI in Cancer Diagnostics
Chapter 12 Company Profiles
  • 20/20 GENE SYSTEMS
  • ABBOTT LABORATORIES
  • ADAPTIVE BIOTECHNOLOGIES INC.
  • AGENDIA NV
  • AGILENT TECHNOLOGIES INC.
  • AKADEUM LIFE SCIENCES
  • AMBRY GENETICS
  • AMOY DIAGNOSTICS CO. LTD.
  • ANGLE PLC
  • APOCELL INC.
  • APOSTLE INC.
  • ARBOR VITA CORP.
  • ARCHER DX
  • AROCELL AB
  • ARUP LABORATORIES
  • ASPIRA LABS
  • ASURAGEN, INC.
  • ATILA BIOSYSTEMS
  • AVIVA BIOSCIENCES
  • BECTON, DICKINSON AND CO.
  • BGI SHENZHEN
  • BIOCARTIS NV
  • BIOCEPT INC.
  • BIODESIX INC.
  • BIOFIDELITY LTD.
  • BIOFLUIDICA INC.
  • BIOLIDICS LTD.
  • BIOLOGICAL DYNAMICS INC.
  • BIOPROGNOS SL
  • BIOTHERANOSTICS INC.
  • BIO-TECHNE CORP.
  • BLUESTAR GENOMICS INC.
  • CANCER GENETICS INC.
  • CARIS LIFE SCIENCES
  • CASTLE BIOSCIENCES INC.
  • CC DIAGNOSTICS BV
  • CELCUITY INC.
  • CELLMAX LIFE
  • CELLULAR ANALYTICS
  • CELL MICROSYSTEMS INC.
  • CELSEE DIAGNOSTICS
  • CHIP DIAGNOSTICS
  • CHRONIX BIOMEDICAL
  • CIRCULOGENE THERANOSTICS
  • CLINICAL GENOMICS TECHNOLOGIES
  • CODIAK BIOSCIENCES
  • DANAHER CORP.
  • DECIPHER BIOSCIENCES
  • DERMTECH
  • DIACARTA INC.
  • DNALYTICS
  • EPIGENOMICS AG
  • EPIC SCIENCES INC.
  • EXACT SCIENCES CORP.
  • FLUXION BIOSCIENCES INC.
  • FREENOME INC.
  • FULGENT GENETICS INC.
  • GENECENTRIC THERAPEUTICS
  • GENEDX INC.
  • GENERA BIOSYSTEMS
  • GENESEQ BIOSCIENCES PTY LTD.
  • GENETRON HEALTH TECHNOLOGIES INC.
  • GENEOSCOPY LLC
  • GENEXOSOME TECHNOLOGIES INC.
  • GRAIL INC.
  • GUARDANT HEALTH INC.
  • HOLOGIC INC.
  • HTG MOLECULAR DIAGNOSTICS INC.
  • IDL BIOTECH
  • ILLUMINA INC.
  • IMMUNIS AI
  • INCELLDX INC.
  • INIVATA LTD.
  • INTERPACE BIOSCIENCES INC.
  • INVITAE INC.
  • INVIVOSCRIBE INC.
  • JBS SCIENCE INC.
  • LABORATORY CORP. OF AMERICA INC.
  • LEXENT BIO INC.
  • LUCENCE DIAGNOSTICS PTE. LTD.
  • LUNGLIFE AI, INC.
  • MDNA LIFE SCIENCES INC.
  • MDXHEALTH INC.
  • MEDGENOME INC.
  • MENARINI SILICON BIOSYSTEMS SPA
  • MIRADX
  • MIR SCIENTIFIC
  • MUTANTDX
  • MY PERSONAL THERAPEUTICS LTD.
  • MYRIAD GENETICS INC.
  • NEOGENOMICS LABORATORIES
  • NEO NEW ONCOLOGY GMBH
  • NODEXUS
  • NOVIGENIX SA
  • NRICH DX
  • NUCLEIX
  • NUPROBE INC.
  • ONCIMMUNE HOLDINGS PLC
  • ONCOCYTE CORP.
  • ONCODNA S.A.
  • OPKO HEALTH
  • OXFORD GENE TECHNOLOGY
  • PACIFIC EDGE LTD.
  • PANGAEA LABORATORY
  • PANGAEA ONCOLOGY
  • PERSONAL GENOME DIAGNOSTICS INC.
  • POLYMEDCO, INC.
  • PREDICINE INC.
  • PROVISTA DIAGNOSTICS INC.
  • QIAGEN NV
  • QUANTUMDX
  • QUEST DIAGNOSTICS INC.
  • RARECYTE INC.
  • RESOLUTION BIOSCIENCE INC.
  • ROCHE HOLDING AG
  • SAGA DIAGNOSTICS AB
  • SANOMICS LTD.
  • SIENNA CANCER DIAGNOSTICS LTD.
  • SINGLERA GENOMICS INC.
  • SISTEMAS GENOMICOS
  • SKYLINEDX BV
  • STAGE ZERO LIFE SCIENCES
  • STRAND LIFE SCIENCES PVT., LTD.
  • SYSMEX INOSTICS GMBH
  • THERMO FISHER SCIENTIFIC INC.
  • THRIVE EARLIER DETECTION CORP.
  • TIZIANA LIFE SCIENCES PLC
  • VORTEX BIOSCIENCES
  • VERACYTE
  • VOLITIONRX
  • XING TECHNOLOGIES LLC
  • YIKON GENOMICS CO. LTD.
List of Tables
Summary Table: Global Market for Next Generation Cancer Diagnostics, by Cancer Site, Through 2025
Table 1: Next Generation Cancer Diagnostics: Scope of Report
Table 2: Large-Scale Initiatives: Cancer Diagnostics Industry
Table 3: Global Market for Next Generation Cancer Diagnostics, by Technology Platform, Through 2025
Table 4: Key Trends in the Market for Next Generation Cancer Diagnostics
Table 5: Next Generation Cancer Diagnostics Industry Subsectors
Table 6: Diagnostic Market Segments
Table 7: Next Generation Diagnostics: Key Analysis Platforms
Table 8: Analysis Platforms and Biomarker Types
Table 9: DNA Microarray Technologies in Cancer Diagnostics
Table 10: Design Features of Protein Microarray Technologies
Table 11: Microfluidic LOAC Types Used in Cancer Diagnostics
Table 12: Advanced Sequencing Technologies
Table 13: Illumina Next Generation Sequencing Workflow
Table 14: Thermo Fisher Scientific’s Next Generation Sequencing Workflow
Table 15: Main Ingredients of PCR Technology
Table 16: PCR Process
Table 17: Advantages of Droplet Digital PCR for Single-Cell Analysis
Table 18: Liquid Biopsy Biomarker Classes
Table 19: Cancer Genomic Sequencing and Liquid Biopsy
Table 20: Single-Cell Analysis to Identify Cancer Driver Mutations
Table 21: Genomics-Based Oncology Workflow
Table 22: Unique Challenges: CTC Capture and Analysis
Table 23: CTC Workflow
Table 24: Cell Differentiators
Table 25: Cell Isolation Technologies
Table 26: CTC Sample Preparation Technologies
Table 27: Single-Cell Analysis Technologies
Table 28: Estimated Annual Solid Biopsy Procedures, U.S., Selected Cancers
Table 29: Main Risks of Needle-Based Tissue Biopsies
Table 30: Factors in Tissue Biopsy
Table 31: Approaches to Avatar-Driven Cancer Diagnostics
Table 32: R&D: Next Generation Cancer Diagnostics
Table 33: Single-Cell Core Research Facilities
Table 34: Population Sequencing Projects
Table 35: Bladder Cancer Diagnostic Tests, 2020
Table 36: Brain Cancer: Next Generation Diagnostics Tests, 2020
Table 37: Annual Breast Cancer Treatment Decisions, U.S., by Cancer Classification, 2020
Table 38: Breast Cancer MDx Technology Platforms, 2020
Table 39: Next Generation Breast Cancer Tests, 2020
Table 40: Next Generation Human Papilloma Virus and Cervical Cancer Screening and Genotyping Tests, 2020
Table 41: Ovarian Cancer Early Screening Formats, 2020
Table 42: Ovarian Cancer: Next Generation Diagnostics Tests, 2020
Table 43: CRC Screening Tests, 2020
Table 44: Colorectal Cancer: Next Generation Diagnostic Tests, 2020
Table 45: Cancer Unknown Primary: Next Generation Diagnostic Tests, 2020
Table 46: Gastric Cancer: Next Generation Diagnostic Tests, 2020
Table 47: Kidney Cancer: Next Generation Diagnostic Tests, 2020
Table 48: Leukemia and Myeloma: Next Generation Diagnostic Tests, 2020
Table 49: Liver Cancer: Next Generation Diagnostic Tests, 2020
Table 50: Five-Year Survival Rates for Non-Small Cell Lung Cancer, 2020
Table 51: Lung Cancer: Next Generation Diagnostic Tests, 2020
Table 52: Lymphoma: Next Generation Diagnostic Tests, 2020
Table 53: Melanoma: Next Generation Diagnostic Tests, 2020
Table 54: Pan-Cancer: Next Generation Diagnostic Tests, 2020
Table 55: Prostate Cancer Next Generation Diagnostic Tests, 2020
Table 56: Thyroid Cancer: Next Generation Diagnostics Tests, 2020
Table 57: Advanced Sequencing Industry Company Positioning
Table 58: End-to-End Sequencing Approaches
Table 59: Long-Read Sequencing Industry
Table 60: Sequencing Informatics Industry
Table 61: PCR Companies
Table 62: Advantages of Droplet Digital PCR for Single-Cell Analysis
Table 63: Digital PCR Liquid Biopsy Industry
Table 64: CTC Separations Industry
Table 65: Liquid Biopsy Assay Industry: Company Focus
Table 66: NGS-Based Liquid Biopsy Market Differentiation
Table 67: Cancer Diagnostics Industry Acquisitions, Jan. 2019-July 2020
Table 68: Cancer Diagnostics Strategic Alliances, Jan. 2019-July 2020
Table 69: Liquid Biopsy: Forces Driving Growth, 2020
Table 70: Limitations of Solid Biopsy in Cancer Applications
Table 71: Low-Frequency Mutation Detection
Table 72: Global Market for Next Generation Cancer Diagnostics, by Cancer Site, Through 2025
Table 73: Ovarian Cancer: Five-Year Survival Rate
Table 74: NIH Liquid Biopsy Early Detection Initiative
Table 75: Global Market for Next Generation Cancer Diagnostics, by Purpose of Analysis, Through 2025
Table 76: MRI and Liquid Biopsy Methods
Table 77: Early Detection: Tissue of Origin Approaches
Table 78: Global Market for Next Generation Cancer Diagnostics, by Test Platform, Through 2025
Table 79: FDA-Approved or CE-Marked Tests with Epigenetic Component
Table 80: Global Market for PCR-Based Cancer Diagnostics, by Cancer Site, Through 2025
Table 81: Global Market for NGS-Based Cancer Diagnostics, by Cancer Site, Through 2025
Table 82: Global Market for Next Generation Cancer Screening/Early Detection, by Cancer Site, Through 2025
Table 83: Global Market for Next Generation Cancer Diagnosis, by Cancer Site, Through 2025
Table 84: Global Market for Next Generation Cancer Monitoring, by Cancer Site, Through 2025
Table 85: Global Market for Next Generation Cancer Therapy Guidance, by Cancer Site, Through 2025
Table 86: Global Market for Breast Cancer Diagnostics, by Analysis Method, Through 2025
Table 87: Global Market for Colorectal Cancer Diagnostics, by Analysis Method, Through 2025
Table 88: Global Market for Lung Cancer Diagnostics, by Analysis Method, Through 2025
Table 89: Global Market for Pan-Cancer Diagnostics, by Analysis Method, Through 2025
Table 90: Global Market for Prostate Cancer Diagnostics, by Analysis Method, Through 2025
Table 91: Global Market for Next Generation Cancer Diagnostics, by Region, Through 2025
Table 92: Patent Activity: Circulating Tumor Cells (CTCs), by Region, Jan. 2010–June 2020
Table 93: Patent Activity: Exosomes, by Region, Jan. 2010-June 2020
Table 94: Patent Activity: cfDNA, by Region, 2010–June 2020
Table 95: Patent Activity: Cancer Biomarkers, by Region, Jan. 2010–June 2020

List of Figures
Summary Figure: Global Market for Next Generation Cancer Diagnostics, by Cancer Site, 2019-2025
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • 20/20 Gene Systems
  • Abbott Laboratories
  • Adaptive Biotechnologies Inc.
  • Agendia Nv
  • Agilent Technologies Inc.
  • Akadeum Life Sciences
  • Ambry Genetics
  • Amoy Diagnostics Co. Ltd.
  • Angle Plc
  • Apocell Inc.
  • Apostle Inc.
  • Arbor Vita Corp.
  • Archer Dx
  • Arocell Ab
  • Arup Laboratories
  • Aspira Labs
  • Asuragen, Inc.
  • Atila Biosystems
  • Aviva Biosciences
  • Becton, Dickinson And Co.
  • BGI Shenzhen
  • Bio-Techne Corp.
  • Biocartis Nv
  • Biocept Inc.
  • Biodesix Inc.
  • Biofidelity Ltd.
  • Biofluidica Inc.
  • Biolidics Ltd.
  • Biological Dynamics Inc.
  • Bioprognos Sl
  • Biotheranostics Inc.
  • Bluestar Genomics Inc.
  • Cancer Genetics Inc.
  • Caris Life Sciences
  • Castle Biosciences Inc.
  • CC Diagnostics Bv
  • Celcuity Inc.
  • Cell Microsystems Inc.
  • Cellmax Life
  • Cellular Analytics
  • Celsee Diagnostics
  • Chip Diagnostics
  • Chronix Biomedical
  • Circulogene Theranostics
  • Clinical Genomics Technologies
  • Codiak Biosciences
  • Danaher Corp.
  • Decipher Biosciences
  • Dermtech
  • Diacarta Inc.
  • Dnalytics
  • Epic Sciences Inc.
  • Epigenomics Ag
  • Exact Sciences Corp.
  • Fluxion Biosciences Inc.
  • Freenome Inc.
  • Fulgent Genetics Inc.
  • Genecentric Therapeutics
  • Genedx Inc.
  • Geneoscopy Llc
  • Genera Biosystems
  • Geneseq Biosciences Pty Ltd.
  • Genetron Health Technologies Inc.
  • Genexosome Technologies Inc.
  • Grail Inc.
  • Guardant Health Inc.
  • Hologic Inc.
  • HTG Molecular Diagnostics Inc.
  • IDL Biotech
  • Illumina Inc.
  • Immunis Ai
  • Incelldx Inc.
  • Inivata Ltd.
  • Interpace Biosciences Inc.
  • Invitae Inc.
  • Invivoscribe Inc.
  • JBS Science Inc.
  • Laboratory Corp. Of America Inc.
  • Lexent Bio Inc.
  • Lucence Diagnostics Pte. Ltd.
  • Lunglife Ai, Inc.
  • MDNA Life Sciences Inc.
  • Mdxhealth Inc.
  • Medgenome Inc.
  • Menarini Silicon Biosystems Spa
  • MIR Scientific
  • Miradx
  • Mutantdx
  • My Personal Therapeutics Ltd.
  • Myriad Genetics Inc.
  • Neo New Oncology Gmbh
  • Neogenomics Laboratories
  • Nodexus
  • Novigenix Sa
  • Nrich Dx
  • Nucleix
  • Nuprobe Inc.
  • Oncimmune Holdings Plc
  • Oncocyte Corp.
  • Oncodna S.A.
  • Opko Health
  • Oxford Gene Technology
  • Pacific Edge Ltd.
  • Pangaea Laboratory
  • Pangaea Oncology
  • Personal Genome Diagnostics Inc.
  • Polymedco, Inc.
  • Predicine Inc.
  • Provista Diagnostics Inc.
  • Qiagen Nv
  • Quantumdx
  • Quest Diagnostics Inc.
  • Rarecyte Inc.
  • Resolution Bioscience Inc.
  • Roche Holding Ag
  • Saga Diagnostics Ab
  • Sanomics Ltd.
  • Sienna Cancer Diagnostics Ltd.
  • Singlera Genomics Inc.
  • Sistemas Genomicos
  • Skylinedx Bv
  • Stage Zero Life Sciences
  • Strand Life Sciences Pvt., Ltd.
  • Sysmex Inostics Gmbh
  • Thermo Fisher Scientific Inc.
  • Thrive Earlier Detection Corp.
  • Tiziana Life Sciences Plc
  • Veracyte
  • Volitionrx
  • Vortex Biosciences
  • Xing Technologies Llc
  • Yikon Genomics Co. Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll